Mirum Pharmaceuticals, Inc. MIRM Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -4.2%+21.8pp | -26%+32.6pp | -58.6%+112pp | -170.3%+736pp | |
| Net margin | -4.5%+21.6pp | -26.1%+61.6pp | -87.7%+88.4pp | -176%— | |
| Returns | |||||
| Return on equity | -8.6%+28.4pp | -37.1%+46.6pp | -83.7%+19.8pp | -103.5%— | |
| Return on invested capital | -43.3%— | —— | —— | -126.4%+152pp | |
| Efficiency | |||||
| Asset turnover | 0.7×+0.2× | 0.5×+0.1× | 0.4×+0.1× | 0.2×+0.2× | |
| Liquidity | |||||
| Current ratio | 2.7×-0.4× | 3.1×-1.3× | 4.5×+1.5× | 2.9×-1.0× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -116.1×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $6.27+32.0% | $4.75-21.9% | $6.08+45.5% | $4.18+5.4% | |
| Valuation | |||||
| Market capitalization | $4.08B+106% | $1.98B+43.9% | $1.38B+91.8% | $718.97M+47.1% | |
| Price / sales | 7.8×+1.9× | 5.9×-1.5× | 7.4×-1.9× | 9.3×-16.2× | |
| Price / book | 13×+4.2× | 8.8×+3.3× | 5.5×+0.5× | 5.1×+1.0× | |
| EV / EBITDA | 1,820.6×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mirum Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Mirum Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
